Gotowe bibliografie tematyczne / Familial breast cancer

Gotowa bibliografia na temat „Familial breast cancer”

Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 29 stycznia 2023

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Spis treści

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Familial breast cancer”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Familial breast cancer"

1

Sukumaran, Shobini, i Kunal Chawathey. "Familial breast cancer". InnovAiT: Education and inspiration for general practice 10, nr 2 (27.12.2016): 82–88. http://dx.doi.org/10.1177/1755738016685893.

Pełny tekst źródła
Streszczenie:
Breast cancer is the most common malignancy in women; it affects about one in eight women. Familial breast cancer typically presents earlier than sporadic breast cancer, and is more often bilateral than in sporadic cases. Ovarian cancer is more common in familial breast cancer. A large number of studies have confirmed an increased breast cancer risk in patients with a significant family history of breast cancer. The breast cancer genotype has an autosomal dominant pattern of transmission. This article considers familial breast cancer and various aspects of breast cancer management in primary care, including the genetics of familial breast cancer, and guidelines on referral to secondary care.
Style APA, Harvard, Vancouver, ISO itp.
2

Hemminki, Kari, Jan Sundquist i Andreas Brandt. "Familial Mortality and Familial Incidence in Cancer". Journal of Clinical Oncology 29, nr 6 (20.02.2011): 712–18. http://dx.doi.org/10.1200/jco.2010.30.5664.

Pełny tekst źródła
Streszczenie:
Purpose An overwhelming majority of data on familial risk in cancer is based on incident cancer, whereas familiality in cancer mortality is largely unknown. If fatal form of cancer was a highly familial subtype, then familial risk for mortality may exceed that of incidence, which would be particularly relevant for clinical decision making and counseling. Patients and Methods The individuals in the nationwide Swedish Family-Cancer Database were classified according to family history of fatal and nonfatal cancer. Familial risks of incident and fatal concordant cancer were calculated for offspring based on their parental family history using a Cox model with hazard ratio (HR); offspring without family history were the reference. Results Most HRs for offspring incident cancers were somewhat higher for fatal compared with nonfatal parental family history. For breast (HR, 1.87 fatal v 1.66 nonfatal; P < .001) and prostate (HR, 2.30 fatal v 1.84 nonfatal; P < .001) cancers, 51.0% of patients with familial breast cancer and 56.6% of patients with prostate cancer had fatal family history. HRs for death in offspring according to a fatal compared with nonfatal family history were significantly increased for colorectal (HR, 1.76 v 1.47, respectively; P = .02), breast (HR, 1.97 v 1.51, respectively; P = .002), and prostate (HR, 2.03 v 1.59, respectively; P = .002) cancers. TNM classification did not seem to differ between the family histories. We showed also that an overwhelming proportion of offspring were diagnosed after the parental death. Conclusion Familial breast, prostate, and colorectal cancers might have a yet unidentified genetic component associated with poorer survival. It may be useful to record survival data in family history records.
Style APA, Harvard, Vancouver, ISO itp.
3

Fourquet, Alain, Dominique Stoppa-Lyonnet, Youlia M. Kirova, Brigitte Sigal-Zafrani i Bernard Asselain. "Familial Breast Cancer". American Journal of Clinical Oncology 32, nr 2 (kwiecień 2009): 127–31. http://dx.doi.org/10.1097/coc.0b013e31817f9e1c.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Weber, Barbara L. "Familial Breast Cancer". Clinical Chemistry 40, nr 4 (1.04.1994): 639–40. http://dx.doi.org/10.1093/clinchem/40.4.639.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Phipps, R. F., i P. M. Perry. "Familial breast cancer." Postgraduate Medical Journal 64, nr 757 (1.11.1988): 847–49. http://dx.doi.org/10.1136/pgmj.64.757.847.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Lalloo, F., i D. G. Evans. "Familial Breast Cancer". Clinical Genetics 82, nr 2 (13.04.2012): 105–14. http://dx.doi.org/10.1111/j.1399-0004.2012.01859.x.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Emery, J. "Familial breast cancer". Family Practice 14, nr 5 (1.10.1997): 422. http://dx.doi.org/10.1093/fampra/14.5.422.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Jones, Corinne, David J. Oliver i Anthony J. Van Merwyk. "Familial male breast cancer". Medical Journal of Australia 164, nr 10 (maj 1996): 640. http://dx.doi.org/10.5694/j.1326-5377.1996.tb122226.x.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Lakhani, Sunil R., Michael J. O'Hare i Alan Ashworth. "Profiling familial breast cancer". Nature Medicine 7, nr 4 (kwiecień 2001): 408–10. http://dx.doi.org/10.1038/86464.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Maxwell, Kara N., i Susan M. Domchek. "Familial Breast Cancer Risk". Current Breast Cancer Reports 5, nr 3 (3.07.2013): 170–82. http://dx.doi.org/10.1007/s12609-013-0117-9.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Familial breast cancer"

1

Collins, N. "BRCA2 in familial and sporadic breast cancer". Thesis, Institute of Cancer Research (University Of London), 2000. http://publications.icr.ac.uk/10070/.

Pełny tekst źródła
Streszczenie:
The breast cancer susceptibility gene BRCA2 is located on chromosome 13q 12-13. Using breast and ovarian cancers from a BRCA2-linked family, loss of the wild type BRCA2 allele was demonstrated in seven out of eight informative cases (87.5%) indicating that BRCA2 was a recessive oncogene. Analysis of 73 sporadic breast tumours and 12 breast cancer cell lines revealed loss of heterozygosity (LOH) in 22 (30%) of the primary tumours and seven (58%) of the breast cancer cell lines. However, it was not clear from these studies that the target for the observed LOH was the gene BRCA2 or RBl at chromosome 13q14 as the region ofLOH included both genes in all but a single case. Despite the presence of elevated levels of LOH, several separate mutation screening studies of sporadic breast and ovarian tumours have shown that somatic mutations of BRCA2 in sporadic breast and ovarian cancer are very rare. To investigate the possibility that other mechanisms of BRCA2 allelic inactivation might be operative, the methylation status of a CpG island within the promoter region of BRCA2 was examined in 64 sporadic breast tumours and 18 breast and ovarian cancer cell lines. Three CpG dinucleotides within this island were unmethylated in all the normal tissue samples (lymphocytes) examined. These three CpG dinucleotides remained unmethylated in all the breast tumours examined. Moreover, expression of BRCA2 in breast and ovarian cancer cell lines was not obviously correlated with evidence of loss of heterozygosity. These analyses indicate that methylation of the promoter region of BRCA2 and possibly other mechanisms of transcriptional silencing are unlikely to be a common mechanism of gene inactivation in these tumours. To investigate the prevalence of BRCA2 mutations, lymphocyte DNAs from a British, population-based series of 617 breast cancers diagnosed before age 45 were screened for mutations. Mutations were detected in 14 women ( 2.3%, 6/14 43% under age 35 and 8/14 57% age 36-45). This study and a parallel study of BRCA1 demonstrate that BRCA2 and BRCA1 make approximately equal contributions to early onset breast cancer in the UK. Moreover, although BRCA1 and BRCA2 account for breast cancer susceptibility in a substantial proportion of multiple case families, they only account for a small proportion of the overall familial risk conferred by an early onset case. This indicates the existence of other susceptibility genes that are more common but confer lower risks than BRCA1 and BRCA2.
Style APA, Harvard, Vancouver, ISO itp.
2

Mohammed, Shehla Nilofer. "Familial breast cancer : a clinicopathological and genetic study". Thesis, King's College London (University of London), 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.299826.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Luo, Liping. "A genetic study on familial breast cancer predisposing genes /". Stockholm, 2002. http://diss.kib.ki.se/2002/91-628-5184-5.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Agenbag, Gloudi. "Molecular genetic analysis of familial breast cancer in South Africa". Thesis, Link to the online version, 2005. http://hdl.handle.net/10019/953.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

MacInnes, Emma G. E. "Psychosocial outcomes in women at increased familial breast cancer risk". Thesis, University of Sheffield, 2017. http://etheses.whiterose.ac.uk/20859/.

Pełny tekst źródła
Streszczenie:
Introduction There are a number of strategies that women with a vastly increased risk of familial breast cancer, particularly those with BRCA 1 and 2 gene mutations, may choose to protect themselves. The main risk management strategies have very different risk and benefit profiles and include enhanced imaging surveillance, use of chemoprevention (SERMs or AIs) and risk reducing surgery. Knowledge of hereditary breast cancer risk and cancer anxiety can impact on quality of life. Options for managing this elevated risk, whilst effective, may have long-term psychosocial consequences. This study aimed to explore the impact of living at risk, to identify the psychosocial outcomes for this group of women and for their partners and to assess factors that impact on risk management decisions and their ultimate decision satisfaction. Methodology A sequential exploratory mixed methods study was used, including a systematic review, a qualitative phase of study, using in-depth, semi-structured interviews with women and partners of women at high risk who had faced these choices, questionnaire development including focus group review and finally a quantitative phase of study using the questionnaire to explore associations and to assess the generalisability of the strength of these findings. (See figure 0.1). Results Generally psychosocial outcomes are acceptable to women with high levels of decision satisfaction, but for a minority, risk reducing measures result in long-term psychosocial morbidity. The more common causes of distress include adverse body image changes, generalised and cancer-specific anxiety and distress. Good support, particularly that of a partner, can reduce this negative impact. Partners struggle to balance existing commitments with the time demands of providing this support. Conclusion Recognising women at increased risk of adverse effects related to their choice of risk management strategy may allow targeted support to enable women to better understand and manage their risk with a reduction in associated psychosocial distress.
Style APA, Harvard, Vancouver, ISO itp.
6

Pharoah, Paul David Peter. "Familial and inherited breast cancer in the East Anglian population". Thesis, University of Cambridge, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.621725.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Kast, Karin, i Kerstin Rhiem. "Familial Breast Cancer: Targeted Therapy in Secondary and Tertiary Prevention". Karger, 2015. https://tud.qucosa.de/id/qucosa%3A71423.

Pełny tekst źródła
Streszczenie:
The introduction of an increasing number of individualized molecular targeted therapies into clinical routine mirrors their importance in modern cancer prevention and treatment. Well-known examples for targeted agents are the monoclonal antibody trastuzumab and the selective estrogen receptor modulator tamoxifen. The identification of an unaltered gene in tumor tissue in colon cancer (KRAS) is a predictor for the patient’s response to targeted therapy with a monoclonal antibody (cetuximab). Targeted therapy for hereditary breast and ovarian cancer has become a reality with the approval of olaparib for platin-sensitive late relapsed BRCA-associated ovarian cancer in December 2014. This manuscript reviews the status quo of poly-ADP-ribose polymerase inhibitors (PARPi) in the therapy of breast and ovarian cancer as well as the struggle for carboplatin as a potential standard of care for triple-negative and, in particular, BRCA-associated breast cancer. Details of the mechanism of action with information on tumor development are provided, and an outlook for further relevant research is given. The efficacy of agents against molecular targets together with the identification of an increasing number of cancer-associated genes will open the floodgates to a new era of treatment decision-making based on molecular tumor profiles. Current clinical trials involving patients with BRCA-associated cancer explore the efficacy of the molecular targeted therapeutics platinum and PARPi.
Style APA, Harvard, Vancouver, ISO itp.
8

Vaittinen, Pauli. "Risk characterization of familial cancer using the Swedish Family-Cancer database with a special reference to breast cancer /". Stockholm, 2003. http://diss.kib.ki.se/2003/91-7349-723-1/.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Renwick, A. A. "Familial breast cancer : are BRCA1 and BRCA2 mutations present in Scotland?" Thesis, University of Aberdeen, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.593342.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Antoniou, A. C. "Developing a comprehensive risk model for familial breast and ovarian cancer". Thesis, University of Cambridge, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.596129.

Pełny tekst źródła
Streszczenie:
The specific aim of this thesis was to combine data on mutation prevalence and risk from both high risk families and population based series, in order to develop a model for familial breast and ovarian cancer which incorporates both the effects of BRCA1, BRCA2 and other genes. The principal methodology used was segregation analysis and the genetic models were constructed using the computer program MENDEL. The first dataset consisted of 112 families containing two or more relatives with epithelial ovarian cancer. BRCA1 and BRCA2 germline mutations were detected in 50% of these families. When the effects of BRCA1, BRCA2 and a third ovarian cancer susceptibility gene were modelled simultaneously none of the models fitted gave significant evidence for a third gene. BRCA1 and BRCA2 were estimated to account for at least 38 % of the excess familial risk of ovarian cancer. Using data on the families of twelve BRCA1 mutation carriers in a study of 374 ovarian cancer cases unselected for family history, the estimated ovarian cancer risk by age 70 was 66% and the corresponding breast cancer risk was 45%. The breast cancer dataset consisted of 1484 women diagnosed with breast cancer under the age 55 from whom blood samples were analysed for mutations in BRCA1 and BRCA2. Using information on breast and ovarian cancer history in first degree relatives, and on the mutation status of the index cases we estimated the effects of BRCA1, BRCA2, a third gene BRCA3 and a polygenic effect. For this purpose the Hypergeometric Polygenic model was implemented in MENDEL.
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Książki na temat "Familial breast cancer"

1

Kessel, A. Genetic testing for breast cancer and familial breast cancer clinics: A needs assessment. Barking: Public Health Directorate, Barking & Havering Health Authority, 1998.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

1963-, Morrison Patrick J., Hodgson S. V i Haites Neva E. 1947-, red. Familial breast and ovarian cancer: Genetics, screening, and management. Cambridge: Cambridge University Press, 2005.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Timothy, Bishop D., Falk Catherine T, MacCluer Jean W i Genetic Analysis Workshop (4th : 1985 : Snowbird, Utah), red. Genetic epidemiology: Applications and comparisons of methods. New York: Liss, 1987.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

We're all in this together: Families facing breast cancer. Kansas City: Andrews and McMeel, 1995.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Not just one in eight: Stories of breast cancer survivors and their families. Deerfield Beach, Fla: Health Communications, 2000.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

A visible wound: A healing journey through breast cancer : with practical and spiritual guidance for women, their partners, and families. Dorset: Element, 1996.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Riggle, Kristina. Real life & liars. Waterville, Me: Kennebec Large Print, 2009.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Riggle, Kristina. Real life & liars. Waterville, Me: Kennebec Large Print, 2009.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

1938-, Stewart Bob, red. Man to man: When the woman you love has breast cancer. New York: St. Martin's Press, 1989.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

You can't fix everything: A husband's perspective on dealing with breast cancer. [Place of publication not identified]: Create Space, 2010.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Części książek na temat "Familial breast cancer"

1

Goldgar, David E., Michael R. Stratton i Rosalind A. Eeles. "Familial breast cancer". W Genetic Predisposition to Cancer, 227–38. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4899-4501-3_14.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Weber, B. L. "Familial Breast Cancer". W Adjuvant Therapy of Breast Cancer V, 5–16. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-79278-6_2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Burwinkel, Barbara, i Rongxi Yang. "Breast Cancer Familial Risk". W Encyclopedia of Cancer, 1–6. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27841-9_6695-2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Burwinkel, Barbara, i Rongxi Yang. "Breast Cancer Familial Risk". W Encyclopedia of Cancer, 653–57. Berlin, Heidelberg: Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-662-46875-3_6695.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Burwinkel, Barbara, i Yang Rongxi. "Breast Cancer Familial Risk". W Encyclopedia of Cancer, 507–10. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_6695.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Narod, Steven A. "Risk Assessment in Hereditary Breast Cancer". W Familial Cancer Control, 95–97. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-77582-6_21.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Malone, Kathleen E., i Kerryn W. Reding. "Inherited Predisposition: Familial Aggregation and High Risk Genes". W Breast Cancer Epidemiology, 277–99. New York, NY: Springer New York, 2009. http://dx.doi.org/10.1007/978-1-4419-0685-4_13.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Andrieu, N., F. Clavel i F. Demenais. "Familial Susceptibility to Breast Cancer". W Recent Progress in the Genetic Epidemiology of Cancer, 29–35. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-75993-2_3.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Walavalkar, Vighnesh, Ashraf Khan i Dina Kandil. "Familial Breast Cancer and Genetic Predisposition in Breast Cancer". W Molecular Pathology Library, 15–37. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2886-6_2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Vourtsis, Athina. "Screening for High-Familial-Risk Women". W Breast Cancer Management for Surgeons, 59–67. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56673-3_6.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Familial breast cancer"

1

Maxwell, Kara N., Thomas Paul Slavin, Jenna M. Lilyquist, Joseph Vijai, Susan L. Neuhausen, Steven N. Hart, Vignesh Ravichandran i in. "Abstract 4265: Risks of familial breast cancer associated with known and proposed breast cancer susceptibility genes". W Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-4265.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Leroy, T., V. Christophe, C. Adenis, L. Vanlemmens i P. Vennin. "Familial transmission of information dealing with BRCA1/2 mutations in hereditary breast and ovarian cancer." W CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-1104.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Hussain, Shehnaz K., Zuo-Feng Zhang, Lorna Kwan, Joyce Seldon i Patricia A. Ganz. "Abstract 2813: Vitamin D, calcium, and dairy intake and familial breast cancer". W Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2813.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Adubeiro, R., AC Antunes, C. Pinheiro, P. Santos, J. Cardoso, JB Pereira-Leal, O. Monteiro Gil, AS Rodrigues, J. Rueff i S. Nunes da Silva. "PO-020 Functional characterisation of variant of unknown significate in familial breast cancer". W Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.65.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Dibbell, Mattie, Deborah Erwin, Detric Johnson, Lina Jandorf, Veronica Meadows Ray i Heather Ochs-Balcom. "Abstract C54: Parity and breastfeeding associations with familial estrogen receptor-negative breast cancer". W Abstracts: Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; September 25-28, 2016; Fort Lauderdale, FL. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7755.disp16-c54.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Curtin, Karen, Leigh Neumayer, Matthew B. Morgan, Matthew A. Stein, Nicola J. Camp, Geraldine P. Mineau, Kerry G. Rowe i Saundra S. Buys. "Abstract P3-07-07: Familial risk of breast density in extended Utah pedigrees". W Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p3-07-07.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Heemskerk-Gerritsen, BA, MJ Hooning, M. Collee, MM Tilanus-Linthorst, CC Bartels, A. van den Ouweland, A. Ansink i C. Seynaeve. "Prevention of primary and contralateral breast cancer by risk reducing salpingo-oophorectomy in high risk women with a BRCA1/2 mutation or familial predisposition." W CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-504.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Flanagan, James, Sibylle Cocciardi, Nic Waddell, Cameron Johnstone, Stephen Henderson, Peter Simpson, kConFab, Leonard da Silva i in. "Abstract 162: DNA methylome in familial breast cancer identifies distinct profiles defined by mutation status". W Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-162.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Weber-Lassalle, N., J. Borde, K. Weber-Lassalle, K. Klaschik, G. Neidhardt, C. Ernst, B. Blümcke i in. "Germline loss-of-function variants in the BARD1 gene are associated with familial breast cancer". W 38. Jahrestagung der Deutschen Gesellschaft für Senologie. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1651818.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Hermel, DJ, WC McKinnon, L. Colello, MS Greenblatt i ME Wood. "Abstract P4-06-17: Expanded panel testing in patients with breast or ovarian cancer in a rural familial cancer program". W Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.sabcs17-p4-06-17.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Raporty organizacyjne na temat "Familial breast cancer"

1

Ursin, Giske. Estrogen Metabolism and Familial Risk of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, październik 1995. http://dx.doi.org/10.21236/ada306474.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Ozcelik, Hilmi. Investigation of Trinucleotide Repeat Expansion in Familial Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, kwiecień 2002. http://dx.doi.org/10.21236/ada405233.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Yakovlev, Andrei Y. Individual Strategies for Breast Cancer Surveillance Based on Aggregated Familial Information. Fort Belvoir, VA: Defense Technical Information Center, styczeń 2001. http://dx.doi.org/10.21236/ada394046.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Yakovlev, A., K. Boucher, A. Tsodikov, R. Kerber i G. Gregori. Individualized Strategies for Breast Cancer Surveillance Based on Aggregated Familial Information. Fort Belvoir, VA: Defense Technical Information Center, lipiec 2002. http://dx.doi.org/10.21236/ada407384.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

King, Mary-Claire, i Warren Winkelstein Jr. Genetic Alterations in Familial Breast Cancer: Mapping and Cloning Genes Other than BRCA1. Fort Belvoir, VA: Defense Technical Information Center, wrzesień 1996. http://dx.doi.org/10.21236/ada328004.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

King, Mary-Claire. Genetic Alterations in Familial Breast Cancer: Mapping and Cloning Genes Other Than BRCAl. Fort Belvoir, VA: Defense Technical Information Center, wrzesień 1997. http://dx.doi.org/10.21236/ada346685.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Khanna, Kum K., George Chenevix-Trench i Sean Grimmond. A Novel Method to Screen for Dominant Negative ATM Mutations in Familial Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, kwiecień 2003. http://dx.doi.org/10.21236/ada416707.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Khanna, Kum K. A Novel Method to Screen for Dominant Negative ATM Mutations in Familial Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, kwiecień 2004. http://dx.doi.org/10.21236/ada425752.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Ahsan, Habibul. CHEK2*1100delC Variant and BRCA1/2-Negative Familial Breast Cancer - A Family-Based Genetic Association Study. Fort Belvoir, VA: Defense Technical Information Center, październik 2007. http://dx.doi.org/10.21236/ada484106.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Zakowski, Sandra G., i Dana H. Bovbjerg. Psychophysiological Reactions and Immunological Sensitivity to Stress in Healthy Women at Familial Risk for Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, styczeń 1997. http://dx.doi.org/10.21236/ada333214.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Familial breast cancer” dla poszczególnych typów źródeł:
Artykuły w czasopismach Rozprawy doktorskie Książki
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii